Novartis AG vs Royal Caribbean Cruises Ltd — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Royal Caribbean Cruises Ltd trades at $307.2 (market cap $82.38B). The key difference: Novartis AG is far larger — about 3.6× Royal Caribbean Cruises Ltd's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| NVS | RCL | |
|---|---|---|
Market Cap | $298.18B | $82.38B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $365.84 |
52-Week Low | $119.31 | $246.71 |
Enterprise Value | $339.50B | $105.02B |
Dividend Yield | 3.02% | 1.62% |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →